Skip to main content

Elicio Therapeutics, Inc.

corporate_fare Company Profile

Elicio Therapeutics, Inc.

ELTX·NASDAQ·Life Sciences·CIK 0001601485

We are a clinical-stage biotechnology company focused on developing new immunotherapies for cancer. Our work targets cancers such as mutant Kirsten rat sarcoma viral oncogene homolog ("mKRAS")-positive pancreatic cancer, colorectal cancer ("CRC"), lung cancer, and other mKRAS-positive cancers. We aim to create effective, ready-to-use immunotherapies by building on recent successes in personalized cancer immunotherapy. Our unique Amphiphile ("AMP") technology is designed to improve how cancer-specific T cells are trained, activated, and multiplied compared to traditional immunotherapy methods. The goal is to help patients maintain long-lasting immune surveillance against cancer. We believe our AMP technology can produce strong T cell responses in patients, which could lead to significant clinical benefits. We think that many existing and developing cancer immunotherapies are limited because they don't effectively reach lymph nodes or fully interact with the immune cells crucial for adaptive immunity. Our AMP technology is specifically designed to deliver its components to lymph nodes to create a strong T cell response, which we believe is essential for an anti-cancer immune response. Our main programs involve cancer immunotherapy candidates that target specific tumor mutations using common neoantigens. This approach allows for an "off-the-shelf" treatment, meaning patients can receive treatment without delays from manufacturing or the higher costs of personalized immunotherapy. Our clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy in a Phase 2 study. ELI-002 7P is designed to stimulate an immune response against mKRAS pancreatic ductal adenocarcinoma ("PDAC"), the most common type of pancreatic cancer. The ELI-002 7P formulation aims to generate broad immune responses against seven Kirsten rat sarcoma viral oncogene homolog ("KRAS") mutations found in approximately 88% of PDAC patients and 25% of all solid tumors, expanding its potential patient population beyond just PDAC.

Elicio Therapeutics, Inc. (NASDAQ:ELTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for ELTX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for ELTX spans 10-Q, 8-K, 10-K/A, 424B5.

Recent high-impact activity:

  • Elicio 10-Q: Q3 Loss Narrows to $8.0M, Going Concern Reiterated, Cash to Q2 2027
  • Elicio Q3 Loss Narrows to $8.0M; Cash Runway Extended to Q2 2027
  • Elicio's Lead Cancer Vaccine Misses Primary Endpoint in Phase 2 Trial
  • Q2 2026 results show a narrower net loss and extended cash runway into Q1 2027
  • Elicio Therapeutics Closes $15M Registered Direct Offering, Funds Clinical Development

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$39.57M
Diluted EPS
-$2.58
Op. Cash Flow
-$36.95M
Free Cash Flow
-$36.97M
Operating Income
-$37.71M
Cash & Equivalents
$18.56M
Total Debt
$9.41M
Debt / Equity
5.75×
Shares Outstanding
17.8M sh
Source: 10-K · filed 2026-04-29 · accession 0001601485-26-000035

Short Interest & Short Volume

5.87 days to cover

FINRA reported short interest of 1,836,661 shares in ELTX as of the October 30, 2026 settlement, a 7.9% increase from the prior period — about 5.9 days to cover at its recent average daily volume. On November 20, 2026, 38.1% of ELTX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)1,836,661 shares as of October 30, 2026
Change vs prior period▲ 7.9%
Days to cover5.87 at avg daily volume of 313,093
Daily short volume (FINRA facilities)38.1% of 72,121 shares on November 20, 2026
5-day average short volume59.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Recent Capital Actions

  • 2026-02-27 Proposed Shelf Only $400M

    a: Fee Rate 0.01381% a: Offering: 6 a: Offering: a: Fee Previously Paid false a: Rule 457(o) true a: Security Type Unallocated (Universal) Shelf a: Maximum Aggregate Offering Price $ 400,000,000.00 a: Fee Rate 0.01381%…

Detected from SEC filings (8-K, S-4, POS AM, 6-K). Last 12 months.
Browse all tickers starting with E →
$1.45
52-week range · as of 2026-11-05 $1.4 – $16
Market cap
$41.05M
Volume
231.6K (0.7× avg)
3-mo avg 316K
Live data · 2026-11-21 03:06 UTC · Market overnight

show_chartPrice Chart

Loading chart...

feed ELTX - Latest Insights

ELTX
Nov 05, 2026, 4:14 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.41
Real-time Price: $1.45 info
Change: +$0.045 (+3%) info
Market Cap: $41.045M info
ELTX
Nov 05, 2026, 4:12 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.41
Real-time Price: $1.45 info
Change: +$0.045 (+3%) info
Market Cap: $41.045M info
ELTX
Oct 23, 2026, 9:00 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $1.78
Real-time Price: $1.45 info
Change: -$0.330 (-19%) info
Market Cap: $41.045M info
ELTX
Aug 13, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.10
Real-time Price: $1.45 info
Change: -$1.65 (-53%) info
Market Cap: $41.045M info
ELTX
Jul 06, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.26
Real-time Price: $1.45 info
Change: -$1.81 (-56%) info
Market Cap: $41.045M info
ELTX
Jul 02, 2026, 6:20 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.16
Real-time Price: $1.45 info
Change: -$2.71 (-65%) info
Market Cap: $41.045M info
ELTX
Jul 02, 2026, 12:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $4.90
Real-time Price: $1.45 info
Change: -$3.45 (-70%) info
Market Cap: $41.045M info
ELTX
Jun 24, 2026, 4:13 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $3.98
Real-time Price: $1.45 info
Change: -$2.53 (-64%) info
Market Cap: $41.045M info
ELTX
Jun 24, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.98
Real-time Price: $1.45 info
Change: -$2.53 (-64%) info
Market Cap: $41.045M info
ELTX
Jun 17, 2026, 8:03 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.33
Real-time Price: $1.45 info
Change: -$0.880 (-38%) info
Market Cap: $41.045M info
ELTX
Jun 15, 2026, 9:21 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $4.77
Real-time Price: $1.45 info
Change: -$3.32 (-70%) info
Market Cap: $41.045M info
ELTX
Jun 15, 2026, 8:19 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $6.10
Real-time Price: $1.45 info
Change: -$4.65 (-76%) info
Market Cap: $41.045M info
ELTX
Jun 01, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $11.00
Real-time Price: $1.45 info
Change: -$9.55 (-87%) info
Market Cap: $41.045M info
ELTX
May 11, 2026, 4:12 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $11.39
Real-time Price: $1.45 info
Change: -$9.94 (-87%) info
Market Cap: $41.045M info
ELTX
May 11, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $11.39
Real-time Price: $1.45 info
Change: -$9.94 (-87%) info
Market Cap: $41.045M info
ELTX
Apr 29, 2026, 4:06 PM EDT
Filing Type: 10-K/A
Importance Score:
8
Price at Filing: $10.32
Real-time Price: $1.45 info
Change: -$8.87 (-86%) info
Market Cap: $41.045M info
ELTX
Mar 16, 2026, 9:19 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $12.20
Real-time Price: $1.45 info
Change: -$10.75 (-88%) info
Market Cap: $41.045M info
ELTX
Mar 16, 2026, 9:18 AM EDT
Filing Type: 424B5
Importance Score:
9
Price at Filing: $12.20
Real-time Price: $1.45 info
Change: -$10.75 (-88%) info
Market Cap: $41.045M info
ELTX
Mar 12, 2026, 4:35 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $10.69
Real-time Price: $1.45 info
Change: -$9.24 (-86%) info
Market Cap: $41.045M info
ELTX
Mar 12, 2026, 4:34 PM EDT
Filing Type: S-3/A
Importance Score:
7
Price at Filing: $10.69
Real-time Price: $1.45 info
Change: -$9.24 (-86%) info
Market Cap: $41.045M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets